Last reviewed · How we verify
Aescin (ESCIN)
Aescin (generic name: ESCIN) is a drug. It is currently in Phase 2 development.
Aescin works by stabilizing blood vessel walls and improving blood flow.
Aescin is a compound that has been studied in clinical trials for various conditions, including trigger point pain, myofascial pain, chronic venous insufficiency, varicose veins, superficial vein thrombophlebitis, and coronavirus infections. The exact mechanism of action of aescin is unknown, but it has been used in combination with ultrasound (phonophoresis) and other treatments in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ESCIN |
|---|---|
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
Imagine your blood vessels are like a stretchy rubber band. Aescin helps keep the rubber band from stretching too much, which can lead to problems like varicose veins. By keeping the blood vessels stable, Aescin helps blood flow more smoothly and reduces swelling.
Approved indications
Common side effects
Key clinical trials
- Effect of Phonophoresis on Trigger Points (NA)
- Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery (NA)
- A Comparison of Recovery After Impacted Wisdom Tooth Removal (PHASE3)
- The Efficacy of Aescin in Combination With Micronized Purified Flavonoid Fraction (MPFF) in the Control of Bleeding and Prevent Recurrence of Acute Internal Hemorrhoids, A Randomized Controlled Trial, A Pilot Study (EARLY_PHASE1)
- The Efficacy of Aescin in Combination With MPFF in the Early Control of Bleeding From Acute Internal Hemorrhoids, A Randomized Controlled Trial (NA)
- Efficacy and Safety of CONAN® Proctological Cream for Treatment of Haemorrhoidal Disease (NA)
- Bromelain and Escin in the Reduction of Postoperative Sequelae in Periodontal and Implant Surgery (NA)
- Escin in Patients With Covid-19 Infection (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aescin CI brief — competitive landscape report
- Aescin updates RSS · CI watch RSS
Frequently asked questions about Aescin
What is Aescin?
How does Aescin work?
What is the generic name of Aescin?
What development phase is Aescin in?
Related
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing